The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2023

Filed:

May. 05, 2020
Applicants:

Biokine Therapeutics Ltd., Nes Ziona, IL;

Biolinerx Ltd., Modiln, IL;

Inventors:

Amnon Peled, Tel-Aviv, IL;

Yaron Pereg, Shoham, IL;

Assignees:

Biokine Therapeutics Ltd., Nes Ziona, IL;

BioLineRx Ltd., Modiin, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/28 (2006.01); A61K 38/17 (2006.01); A61K 38/04 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 38/10 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1761 (2013.01); A61K 38/04 (2013.01); A61K 38/10 (2013.01); A61K 38/395 (2013.01); A61K 39/12 (2013.01); A61K 39/3955 (2013.01); A61K 47/646 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); A61K 2039/55522 (2013.01); C07K 2317/76 (2013.01);
Abstract

Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.


Find Patent Forward Citations

Loading…